« Back to Record
Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-2
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/366858



